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Introduction
Naturally occurring regulatory CD4CD25hi T (Treg) cells are able
to actively suppress immune responses and play an essential role
in the homeostasis of immune reactions and tolerance [1]. Treg cell
development and function crucially depend on the transcription
factor FOXP3. This is compellingly illustrated by the fact that 
lack of FOXP3 leads to the development of fatal autoimmune
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Abstract
Recent evidence suggests that regulatory pathways might control sustained high levels of FOXP3 in regulatory CD4CD25hi T (Treg)
cells. Based on transcriptional profiling of ex vivo activated Treg and helper CD4CD25 T (Th) cells we have identified GARP (glycopro-
tein-A repetitions predominant), LGALS3 (lectin, galactoside-binding, soluble, 3) and LGMN (legumain) as novel genes implicated in
human Treg cell function, which are induced upon T-cell receptor stimulation. Retroviral overexpression of GARP in antigen-specific Th
cells leads to an efficient and stable re-programming of an effector T cell towards a regulatory T cell, which involves up-regulation of
FOXP3, LGALS3, LGMN and other Treg-associated markers. In contrast, overexpression of LGALS3 and LGMN enhance FOXP3 and
GARP expression, but only partially induced a regulatory phenotype. Lentiviral down-regulation of GARP in Treg cells significantly
impaired the suppressor function and was associated with down-regulation of FOXP3. Moreover, down-regulation of FOXP3 resulted in
similar phenotypic changes and down-regulation of GARP. This provides compelling evidence for a GARP-FOXP3 positive feedback loop
and provides a rational molecular basis for the known difference between natural and transforming growth factor- induced Treg cells
as we show here that the latter do not up-regulate GARP. In summary, we have identified GARP as a key receptor controlling FOXP3 in
Treg cells following T-cell activation in a positive feedback loop assisted by LGALS3 and LGMN, which represents a promising new system
for the therapeutic manipulation of T cells in human disease.
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lymphoproliferative disorder in mouse and man [1].
Consequently, FOXP3-deficient recombinant mice or the natu-
ral mutant scurfy exhibit an analogous immune pathology due
to a lack of regulatory T cells that are able to actively suppress
immune responses against self antigens [1–3]. In agreement,
FOXP3 expression is found in Treg cells with the onset of their
development in thymus.
FOXP3, a member of the winged-helix/forkhead transcription
factors, has been well characterized as transcriptional repressor of
effector cytokines like interleukin-2 (IL-2) [4]. This suppressor
function depends not only on direct promoter occupancy but also
on interactions with other proteins, including histone acetyltrans-
ferase and class II histone deacetylase [5], runt-related transcription
factor 1 (RUNX1) [6] and NFAT [7]. Besides this well-described
negative impact on transcription, recent evidence accumulated
that FOXP3 also positively modulates transcription. Many FOXP3-
binding promoter regions in mice include FOXP3-induced genes,
e.g. Nrp1, CTLA4, GITR and CD25 [8–10].
Although FOXP3 expression in murine CD4 T cells specifically
marks regulatory T cells, an important difference has become
apparent recently between CD4 T cells of man and mouse.
Following T-cell receptor (TCR) activation, human effector
CD4CD25 T (Th) cells up-regulate FOXP3 protein similar to
other markers of T-cell activation including CD25 and CTLA4, and
produce effector cytokines like IL-2 and interferon- despite the
presence of FOXP3 [11–13]. It follows that specific high level of
FOXP3 expression in human Treg cells requires exclusive control
mechanisms to explain the qualitative and quantitative differences
of FOXP3 expression between human activated Th and Treg cells or
as suggested recently, a higher-order regulation [14].
To gain new insights into the differential regulation of FOXP3,
we used whole genome transcriptom analysis of resting and acti-
vated CD4CD25hi Treg cells and their respective CD4CD25 Th
cell counterparts to identify Treg-specific genes that might control
the regulatory phenotype.
Materials and methods
Cell isolation
Treg cell line derived from sorted CD4CD25hi Treg cells and alloantigen-
specific Th cell lines derived from sorted CD4CD25 T cells from
peripheral blood of healthy donors used in this study have been charac-
terized and described previously [15]. Thymic tissue was obtained from
otherwise healthy children undergoing cardiac surgery (n  7, age range
4 days to 3 years) and freshly processed. Thymocytes were isolated as
described recently [16]. In brief, thymocytes were released by mechani-
cal homogenization and CD4CD8CD25, CD4CD8CD25,
CD4CD8CD25 and CD4CD8CD25 T-cell subsets were separated
by magnetic beads or on a FACSAria (Becton Dickinson, San Jose, CA,
USA). The study was approved by the ethical committee of the Helsinki
University Hospital. Informed consent was obtained from the parents 
of the children.
Culture medium
IMDM, supplemented with 10% foetal calf serum, 100 U/ml peni-
cillin/streptomycin, non-essential amino acids and 2 mM glutamine (PAA
Laboratories, Linz, Austria) was used for established T-cell cultures.
Stimulation of human freshly sorted CD4CD25hi and CD4CD25 T cells
for array analysis was done using IMDM, supplemented with 1% heat-
inactivated human serum, 50 g/ml gentamicin and 2 mM glutamine (PAA
Laboratories). Recombinant human IL-2 was used at indicated concentra-
tions between 5 and 100 U/ml. Human transforming growth factor- (TGF-
) (R&D Systems, Inc., Minneapolis, MN, USA) was used at 10 ng/ml.
Antibodies (Abs) and immunization
For immunostaining PE-, FITC-, APC- and CyChrom-conjugated mAbs
against CD4 (RPA-T4), CD8 (53–6.7), CD25 (M-A251), CTLA4 (BNI3),
CD83, CD33, lectin, galactoside-binding, soluble, 3 (LGALS3) (B2C10; all
from BD Bioscience, San Jose, CA, USA), PE-conjugated and ALEXA-
Fluor467-conjugated mAb against FOXP3 (206D) and respective isotype
controls (MOPC; BioLegend, Inc., San Diego, CA, USA) were used accord-
ing to the manufacturer’s instructions. Anti-CD3ε (TR66, produced from
hybridoma supernatants; and HIT3a, BD) and anti-CD28 (CD28.2, BD) were
used for T-cell stimulation. Monoclonal antibodies against human glycopro-
tein-A repetitions predominant (GARP) were generated according to stan-
dard protocols (www.sysy.com/mabservice.html). Briefly, HIS-tagged
human GARP ectodomain (pos. 23 to 612) was bacterially expressed in E.
coli, purified by affinity chromatography and used for immunization of three
8 to 10 weeks old Balb/c females. Draining lymph node cells were isolated
and fused with the mouse myeloma cell line P363Ag.653 (ATCC CRL-
1580). Clones used in this study, mAb 272G6 and 50G10, were cloned two
times by limiting dilution. Similarly, an epitope specific mAb 272G6 was
raised by immunization against a synthetic GARP peptide (position
296–308: GWSALPLSAPSGN, kindly provided by Dr. W. Tegge, HZI). For
cell surface detection of GARP mAb 272G6, a goat antimouse Ig-Biotin, and
Streptavidin-PE (both Southern Biotechnology Associates, Inc.,
Birmingham, AL, USA) were used. Loading control was performed with
either anti-tubulin mAb 3A2 (Synaptic Systems, Goettingen, Germany) or
Comassie staining of the blot. Western blot detection of legumain (LGMN)
was detected using anti-LGMN mAb as described (clone 6E3; provided by
C. Watts, Department of Biochemistry, University of Dundee, UK) [17].
T-cell functional assays
T-cell proliferation and suppressor activity were assessed by stimulating 
3  104 T cells in triplicates with irradiated LG2-EBV B cells with or with-
out IL-2 in 96 flat-bottom microtiter plates (Nunc, Wiesbaden, Germany).
For transwell experiments Th cells were stimulated in 96 flat-bottom plates
separated by 0.2-m-pore transwell inserts (Greiner bio-one,
Frickenhausen, Germany) from the T cells above the transwell. Cells were
pulsed with 1 Ci/well of [3H]-thymidine after 72 hrs for the final 16 hrs.
Retroviral transduction of human 
alloantigen-specific Th cells
The cDNA encoding human GARP was amplified from plasmid cDNA
(kindly provide by Dr. Birnbaum [18]), human LGMN and LGALS3 were
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amplified from human Treg cell cDNA using high fidelity PFU polymerase
(Promega, Madison, WI, USA) and specific primers (see supplemental
Experimental Procedures). PCR products were cloned into pCR4.1 TOPO
(Invitrogen, Carlsbad, CA, USA), sequenced and inserted into a pMSCV-
based retroviral vector encoding an enhanced green fluorescent protein
(GFP) under the control of an IRES sequence. The FOXP3 construct as well
as production of retroviral supernatants and T-cell transduction have been
described recently [15]. Successfully transduced T cells (GFP) were
sorted and expanded in culture by antigen-specific re-stimulation using
irradiated LG2-EBV B cells and IL-2 for several months as described [15];
in general, after sorting up to four rounds of re-stimulations were needed
to expand sufficient numbers of transduced cells until first functional and
phenotypic testing were done.
Lentiviral down-regulation of GARP and FOXP3 
in human Treg cells
GARP and FOXP3 specific targeting sequences (siGARP4: 5	-GCC TGC ATA
CCC TCT CAC T-3	; siFOXP34: 5	-GCC TGC ATA CCC TCT CAC T-3	) were
cloned into pSuper as recommended by the manufacturer (OligoEngine,
Seattle, WA, USA). Digestion with Sma I and Hinc II released an H1-promoter
driven small-interfering RNA (siRNA) cassette, which was cloned into SnaB
I site of plasmid pHR-SIN-S carrying GFP as selection marker; an irrelevant
control siRNA (siGL4) served as control (kindly provided by Dr. M. Scherr,
Department Hematology and Oncology, Hannover Medical School, Hannover,
Germany) [19]. VSV.G-pseudo-typed lentiviral particles were generated by
calcium-phosphate co-transfection of 293T cells. Treg cells were infected by
spin-infection with lentiviral supernatants and 8 g/ml polybrene.
Successfully transduced Treg cells (GFP) were sorted and kept in culture by
antigen-specific re-stimulation using irradiated LG2-EBV B cells and IL-2.
Semi-quantitative and quantitative RT-PCR
Total RNA was isolated from CD4 T cells using RNAeasy (Qiagen, Hilden,
Germany) or nucleospin RNA-II (Macherey Nagel, Düren, Germany). cDNA
synthesis was done using oligo-dT primers and superscript II reverse tran-
scriptase (Invitrogen). For semi-quantitative RT-PCR, threefold dilutions of
cDNA samples, starting with the first dilution were normalized to the expres-
sion of RPS9 and tested with specific primers (see supplemental
Experimental Procedures). Quantitative real-time PCR was performed on an
ABI PRISM 7000 cycler (Applied Biosystems, Foster City, CA, USA) using the
SYBR Green PCR kit (Stratagene, La Jolla, CA, USA) and primers specific for
primers (see supplemental Experimental Procedures) as described [15].
Expression of GARP, LGALS3 and LGMN mRNA in thymic T-cell subsets
were quantified as described above. For quantitative analysis of FOXP3
mRNA in thymic T-cell subsets TaqMan Universal PCR master mix and com-
mercially available pre-designed intron-spanning primer-probe assay were
used (Hs00203958_m1; Applied Biosystems). Residual genomic DNA was
removed by DNAse I (Sigma-Aldrich, St. Louis, MO, USA) before cDNA syn-
thesis. Results represent the relative expression normalized to -actin
(Hs99999903_m1, Applied Biosystems). The samples were analysed by
using the iCycler iQ RealTime PCR instrument (Bio-Rad, Hercules, CA, USA).
GARP structural analysis
Described in detail in supplemental Experimental Procedures.
GeneChip assays and microarray data analysis
Transcriptome analysis of freshly isolated and anti-CD3/IL-2 or anti-CD3/anti-
CD28/IL-2 stimulated CD4CD25hi-derived Treg cells and CD4CD25 T cells
of individual donors were analysed following RNA amplification as described
recently [8] using human genome U133 A and B arrays (Affymetrix, Santa
Clara, CA, USA). Selection criteria for differentially expressed genes were: (1)
signal fold-change of more than twofold or (2) similar signal change as being
either similarly increased (I, including marginal increased, MI) or decreased
(D, including marginal decreased, MD) in anti-CD3/IL-2 and anti-CD3/anti-
CD28/IL-2 stimulated CD4CD25hi Treg cells compared to their respective
controls according to MAS 5.0 software algorithms (www.affymetrix.com/
support/technical/manuals.affx: Microarray Suite User’s Guide, Version 5.0).
Differentially expressed genes of Treg cells, and GARP-, FOXP3- or GFP-trans-
duced Th cells were analysed on U133 PLUS 2.0 arrays after stimulation of the
cells for 3 days with anti-CD3/IL-2. All data were compared to ThGFP cells.
Analysis of microarray data was performed with the Affymetrix GCOS 1.2 soft-
ware (MAS v5 algorithm, Affymetrix). For normalization all array experiments
were scaled to a target intensity of 150, otherwise using the default values of
GCOS 1.2. Data selection criteria for cluster analysis were: (1) signal intensi-
ties were transformed into log2 values and differences between signal log2
intensities (signal log2 ratio, SLR) for a specific ProbeSet should be equal to
or exceed at least once the value 2 and (2) the signal intensity should exceed
at least once 100. The next cycle of selection excludes genes were their dis-
tance between maximal and minimal SLR is below two. K-means clustering
was used to group similar expression changes based on SLR together.
Accession code
Microarray data have been deposited at Geo database (GSE13017 and
GSE13234).
Results
GARP, an early-induced gene of human
CD4CD25hi Treg cells
We isolated CD4CD25hi Treg cells and CD4CD25 Th cells from
human peripheral blood of healthy donors by cell sorting. Isolated
T cells were either directly analysed or stimulated for 1 day with
anti-CD3/IL-2 or anti-CD3/anti-CD28/IL-2 before gene expression
profiling. With this approach we identified the orphan receptor
GARP (also known as LRRC32) as gene exclusively induced in
CD4CD25hi Treg cells upon stimulation (Fig. 1A, Table S1). To
confirm these results CD4CD25hi Treg cells and CD4CD25 Th
cells were isolated from independent donors and analysed directly,
12, 48 hrs and more than 1 week after stimulation with anti-
CD3/anti-CD28/IL-2 by quantitative real-time RT-PCR. This analy-
sis revealed the exclusive induction of GARP in CD4CD25hi Treg
cells over 12 to 48 hrs following TCR stimulation and sustained
mRNA expression thereafter, accompanied by up-regulation of
FOXP3 (Fig. 1B). These GARPhi Treg cells were functionally con-
firmed to be suppressor cells (Fig. 1C).
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reconstruction together with a ribbon representation of the model of human GARP. The asparagine residues of putative glycosylation sites are indicated
as space-filling spheres coloured according to atom type (carbon light brown, oxygen red, nitrogen blue). (F) Western blot analysis of alloantigen-
 specific Treg and Th cells without or with retroviral overexpression of GARP, FOXP3, LGMN, LGALS3, and GFP under resting and activated conditions
using anti-CD3/IL-2 stimulation for 3 days using anti-GARP specific mAb 50G10; anti-Tubulin served as loading control. (G) Detection of cell surface
expression of wt GARP and mutant GARP
PDZ expressed in 293 cells (left panel) using mAb 272G6 compared to WB detection in the same cells (insert)
using mAb 50G10. (H) Treg and Th cells as in (F) were treated for 4 hrs with PMA (40 ng/ml) and ionomycine (0.5 g/ml) to induce up-regulation of
the early-induced gene CD83 (lower panel) and tested for surface expression of GARP (upper panel).
Fig. 1 GARP is exclusively
induced in CD4CD25hi-
derived Treg cells. (A) 
Human CD4CD25hi Treg and
CD4CD25 T cells were
sorted to a purity of 99%
and analysed ex vivo (no
stim.) and 24 hrs after stimu-
lation using anti-CD3/IL-2 and
anti-CD3/anti-CD28/IL-2.
GARP signal intensity as
determined by GenChip analy-
sis and is represented nor-
malized to the signal of RPS9.
(B) Confirmation by real-time
RT-PCR analysis of GARP
(upper panel) and FOXP3
(lower panel) mRNA expres-
sion in independently 
sorted CD4CD25hi Treg and
CD4CD25 Th cells analysed
ex vivo (t0h), 12, 48 hrs 
and day 9 after stimulation
with anti-CD3/anti-CD28
Dynalbeads at a ratio of 1:1
and IL-2. Relative mRNA
expression of CD4CD25 Th
cells at time t0 was arbitrarily
set as 1. (C) The same
CD4CD25hi Treg cells as in
(B) were tested for suppres-
sor function of alloantigen-
stimulated CD4CD25 Th
cells at a ratio of 1 to 1.
Proliferation was assessed at
day 3 by measuring incorpo-
ration of H3-thymidin (cpm).
(D) Fourier shell correlation of
refinement process and
EOTEST are shown (left part).
The values 1.4 and 1.8 corre-
spond to the estimated reso-
lution of 14 and 18 Å. The
insert is an asymmetric trian-
gular showing the distribution
of the particles’ orientations.
Representative gallery of pro-
jections of the single particles
alternating with the corre-
sponding class averages is
shown on the right. (E)
Surface display of the 3D
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GARP represents a leucine-rich repeat receptor of 662 amino
acids. The extracellular portion of GARP is almost entirely com-
posed of leucine-rich repeats [18] with high homology to the
ectodomain of Toll-like receptor (TLR)-3 (Fig. S1A). The structure
of the ectodomain of TLR3 is a horseshoe-shaped solenoid,
largely masked by carbohydrate. One face of TLR3 remains glyco-
sylation free, suggesting a potential role in ligand binding and
oligomerization [20]. Interestingly, modelling of GARP using the
structural coordinates of TLR3 reveals that three of five potential
glycosylation sites of GARP are positioned on the concave face,
similar to TLR3. Based on this simulation, a glycolysation-free
area and two prominent loops at residues 296–308 and 421–432
are predicted in GARP as potential ligand binding and oligomeriza-
tion sites (Fig. S1B) [20]. We used electron microscopy and 3D
image reconstruction to confirm the horseshoe-shaped appear-
ance of GARP (Fig. 1D and E).Whereas TLRs share a cytoplasmic
Toll/IL-1 receptor domain, GARP does not contain such a well-
defined signalling domain within its 14 aa short cytoplasmic tail.
However, the four C-terminal amino acids Gln-Tyr-Lys-Ala of GARP
exhibit homology to the PDZ (post-synaptic density protein-95,
post-synaptic disc large and zona occludens-1) class II binding
motif, a modular interaction domain [21].
To confirm expression of GARP protein in human activated Treg
cells, we immunized mice with bacterially expressed human GARP
protein or a synthetic peptide GARP296–308, respectively, to generate
anti-GARP specific mAbs. Immunoblot analysis using anti-GARP
mAb 50G10 revealed GARP protein expression in activated Treg cells
but not in alloantigen-specific Th cells (Fig. 1F). But unlike cell sur-
face expression in epithelial 293 cells transfected with GARP using
with the epitope specific anti-GARP296–308 mAb 272G6 (Fig. 1G),
detection on Jurkat T cell tranduced with GARP nor on Treg cells was
detected (data not shown). Even stimulation using PMA/ionomycin
for 4 hrs, effectively up-regulating the early-induced gene CD83 that
is differentially induced in Treg versus Th cells [22], did not let to
detectable surface expression of GARP using mAb 272G6 on Treg
cells. Because mAb 272G6 also did not detect surface expression
on human platelets, which have been reported recently to have
GARP surface expression [23], the respective GARP epitope recog-
nized by mAb 272G6 might in some way be mask at least on human
T cells and platelets. Moreover, the amount surface expression of
GARP in 293 cells depended on the presence of an intact C-termi-
nal PDZ domain, because mutation of the C-terminal Ala towards a
Ser impaired protein expression of GARP (Fig. 1G).
Thus, GARP represents an orphan TLR specifically induced in
human CD4CD25hi-derived Treg cells following TCR activation sug-
gesting a potential contribution of GARP to the regulatory phenotype.
Ectopic expression of GARP in human 
antigen-specific Th cells confers sustained
expression of FOXP3
To investigate the potential contribution of GARP to the regulatory
phenotype, we used a retroviral overexpression system in a
human alloantigen-specific effector Th cells with a construct that
included enhanced GFP as marker linked by an internal ribosome
entry site to the gene of interest as described recently [15].
Successfully transduced Th cells (ThGARP) were isolated accord-
ing to their expression of GFP by cell-sorting and expanded in cul-
ture by antigen-specific re-stimulation (as described in ‘Materials
and methods’). The same alloantigen-specific Th cells retrovirally
transduced in parallel with GFP alone (ThGFP) served as negative
control. Transduction with FOXP3 (ThFOXP3) and an established
and well-characterized Treg cell line [15] were included for com-
parison. Immunoblot analysis confirmed the ectopic expression of
GARP in ThGARP cells (Fig. 1E).
Flow-cytometry of ThGARP cells under resting conditions
revealed sustained high levels of FOXP3 protein expression com-
parable to FOXP3-transduced allo-reactive Th cells and Treg cells
(Fig. 2A). This was accompanied by up-regulation of the Treg-mark-
ers CD25, CTLA4, -galactoside binding protein LGALS3 [15] and
CD27 [24] in ThGARP and ThFOXP3 cells, whereas CD33 (see
below), GITR and CD83 [22] were not similarly affected (Fig. 2B).
We further wanted to test whether TCR activation of ThGARP
cells would enhance FOXP3 expression. As presented in Fig. 2C,
antigen-specific stimulation using allogeneic EBV B cells and IL-2
profoundly increased FOXP3 as well as LGALS3 expression in Th
cells that ectopically expressed GARP or FOXP3 but not ThGFP
cells. Important to note, that the conversion of an effector towards
a regulatory phenotype observed represents a process that needs
repeated rounds of TCR stimulations before being established
(data not shown).
Thus, ectopic expression of GARP in antigen-specific Th cells
modulated the TCR-dependent signalling of effector T cells
towards the conversion into regulatory T cells including sustained
expression of FOXP3 und up-regulation of Treg markers CD25,
CTLA4, LGALS3 and CD27. Transduction of FOXP3, in contrast,
did not result in a similar Treg-like expression of GARP while CD25,
CTLA4, LGALS3 and CD27 were similarly induced.
GARP induces a Treg-signature 
of transcriptional control
ThGARP cells exhibited a phenotype that resembled activated Treg
cells. We, therefore, wanted to establish whether such cells would
show also impaired IL-2 transcription like Treg cells. Following
stimulation of ThGFP cells with anti-CD3/IL-2, transcription of 
IL-2 was effectively induced (Fig. 3A). In contrast, ThGARP cells
revealed severe repression of IL-2 transcription similar to Treg and
ThFOXP3 cells (Fig. 3A).
We further tested genes known to be up-regulated in Treg cells
and alloantigen-specific Th cells transduced with FOXP3 using
semi-quantitative RT-PCR including the endosomal cysteine-
protease LGMN, the ubiquitin-like gene diubiquitin (UBD) and 
IL-1 receptor 2 (IL1R2) [15, 25]. Similar to FOXP3-transduced Th
cells, GARP-transduction led to the up-regulation of such genes
(Fig. S2A). The induction of LGMN was further confirmed at the
protein level by immunoblot analysis (Fig. S2B).
3348
Because ectopic expression of GARP in alloantigen-specific Th
cells redirected TCR signalling towards transcriptional regulation
normally associated with FOXP3 in CD4CD25hi-derived Treg cells,
we extended this analysis by gene expression profiling. Cluster
analysis of expression profiles derived from anti-CD3/IL-2 stimu-
lated Treg cells compared to Th cells transduced with GARP, FOXP3
or GFP revealed that 1286 out of 8973 differentially expressed
transcripts were similarly up-regulated in ThGARP, ThFOXP3 and
Treg cells compared to ThGFP cells (cluster 5 in Fig. 3B, Table S2).
These genes represent a Treg-signature, because many of these
genes are known to be expressed at high levels in Treg cells or
induced by FOXP3 in alloantigen-specific Th cells, i.e. FOXP3,
GARP, LGALS3 [15, 25], CTLA4, LAG3 [26], CD28 [15], CD47
[27], CD62L, CD27 (TNFRSF7) [24], TNFRSF4 (CD134) [28],
TNFRSF9 (CD137) [29], IL1R2 [15], LGMN [15] and DICER [30]
(Table S2, Fig. 3B).
Besides known genes of Treg-signature induced by GARP, novel
genes were revealed. These included the intracellular Ca2
channel ryanodine receptor-1 (RYR-1), NAD-linked 15-hydrox-
yprostaglandin dehydrogenase (HPGD), protein tyrosine phos-
phatase type IVA member 3 (PTP4A3), TOB1 (transducer of
ERBB2, 1), ISG20 (interferon stimulated exonuclease gene 20 kD),
Kruppel-like factors 2 and 8 (KLF-2, -8), inhibitor of DNA binding 3
(ID3), the early growth response gene-1 and CD33 (Table S2).
These genes were all expressed at significant higher levels in 
Treg, ThFOXP3 and ThGARP cells compared to the ThGFP control.
A confirmation of the differential expression of the selected genes
CPE (carboxypeptidase E), RYR-1 and HPGD under resting and
activated conditions by semi-quantitative RT-PCR is presented 
in Fig. S3A.
This extended Treg-signature revealed up-regulation of KLF-2,
known to be sufficient to program T-cell quiescence [31]. In
agreement, the genes PTP4A3, KLF-8 and ISG20, which have been
recently described to be induced by KLF-2 [32] were found  
up-regulated. By quantitative real-time RT-PCR we confirmed that
retroviral overexpression of GARP and FOXP3 in alloantigen-
 specific Th cells indeed induced higher levels of KLF-2 expression
compared to ThGFP cells (Fig. 3C). Thus, a potential role of KLF-2
in the regulation of Treg cell quiescence is suggested.
The sialic-acid binding myeloid receptor CD33 represents a
negative regulator binding SHP-1/SHP-2 protein tyrosine phos-
phatases [33]. Although CD33 is predominantly expressed in
Treg cells (Fig. 2B), a minor portion of antigen-specific Th cells
reveal similar high levels. Thus, we separated antigen-specific
Th cells according to their different levels of CD33 expressing by
cell sorting. Such CD33hi Th cells express higher levels of
FOXP3 compared to their CD33lo Th cell counterparts following
anti-CD3/-CD28/IL-2 (Fig. 3D), although they do not show any
difference in their proliferative capacity (data not shown).
Similarly, CD33hi Th cells up-regulate higher levels of CD83 
following activation (Fig. 3E) although not reaching Treg
levels, suggesting an interrelation between CD33 expression in
T cells with FOXP3 and FOXP3-regulating gene products like
CD83 [22].
Importantly, some genes in the transductants did not reach the
high level typical for Treg cells, e.g. CPE (Fig. S3A) or GITR and
CD83 (Fig. 2B). Therefore, differential expression of such genes
might explain why the phenotype of GARP- and FOXP3-transduced
Th cells is not totally equivalent to Treg cells.
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Fig. 2 Ectopic expression of GARP in human alloantigen-specific Th
cells induces sustained expression of FOXP3. (A) Th cells as in Fig. 1F
were analysed for FOXP3 and (B) CD25, CTLA4, LGALS3, CD27, CD33,
GITR and CD83 expression by flow cytometry under resting conditions.
(C) The same cells as in (A) were stimulated for 3 days with cognate
antigen and 50 U/ml IL-2 and analysed for FOXP3 and LGALS3 protein
expression. Gates for figures (A–C) were set according to non-stained
control (CD25) or isotype control (CTLA4, LGALS3, FOXP3, CD33,
CD83, GITR) represented as shaded histogram (A, B) or set as quadrant
(C); percentage of positive cells is indicated. Treg cells were included for
comparison (A–C).
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Together these results clearly show that ectopic expression of
GARP in alloantigen-specific Th cells was sufficient to modulate
effector-type TCR signalling towards Treg-like sustained FOXP3
expression and with that induced most features of the transcrip-
tional signature of Treg cells.
GARP impairs ionomycin-induced activation 
of NFAT independent of FOXP3
Because ThGARP cells show sustained high levels of FOXP3, poten-
tial FOXP3-independent effects of GARP cannot be assessed. Thus,
for different levels of CD33 expression (ThCD33 and ThCD33 cells, respectively) by cell sorting following stimulation for 3 days using cognate antigen and
IL-2. Isotype control  grey filled, FOXP3  bold black. (E) The same cells as in (D) were analysed for cell surface CD83 and CD33 expression follow-
ing stimulation with cognate antigen and IL-2 for 3 days. (F) A5 cells, transduced with GARP, mutant GARP
PDZ or control lentiviral vector were analysed
for GFP expression without (grey filled) and with 1 g/ml Ionomycine stimulation for 2 (thin line) and 4 (thick line) hrs (upper panel);% GFP is repre-
sented. Lower panel represents the corresponding cell surface expression of GARP, detected with mAb 272G6 as in Fig. 1.
Fig. 3 GARP induces Treg-
signature of transcriptional
control. (A) Resting and
anti-CD3/IL-2 stimulated T
cells as in Figs 1 and 2
were analysed for mRNA
expression of IL-2 by real-
time RT-PCR. The individ-
ual fold change of relative
mRNA expression of indi-
cated Th and Treg cells were
compared to ThGFP cells,
arbitrarily set as 1, is indi-
cated.; n.d.  not detected.
(B) K-Means clusterization
of significantly regulated
genes in Treg, ThGARP and
ThFOXP3 cells compared to
ThGFP cells, all stimulated
for 3 days with anti-
CD3/IL-2. The heat map
represent signal log ratios.
Numbers correspond to
clusters of Table S2. (C)
Real-time RT-PCR analysis
of KLF-2 expression in
anti-CD3/IL-2 stimulated
Th cells transduced with
GARP, FOXP3 or GFP.
Relative mRNA expression
of ThGFP cells was arbitrar-
ily set as 1 (upper panel).
Real-time RT-PCR analysis
of KLF-2 mRNA in Th cells
transduced with LGALS3
and LGMN; Th cells trans-
duced with GFP, GARP, and
parental cells without
transduction (ThGFP-)
served as control (cell line
ThB). Relative mRNA
expression of ThGFP- cells
was arbitrarily set as 1
(lower panel). (D) FOXP3
expressio5n in antigen-
specific Th cells separated
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we transduced A5 hybridoma T cells, which express a GFP-reporter
under control of a basal NFAT promoter described recently [34],
with GARP, mutant GARP
PDZ or control vector. After stimulation
with ionomycine for 2 and 4 hrs, flow-cytometry revealed a sever
impairment of NFAT-dependent GFP induction (Fig. 3F), showing
that GARP mainly affects NFAT activation in the absence of FOXP3.
Moreover, cross-linking GARP via plate-bound mAb 272G6 did not
block nor enhance these results in A5GARP cells (data not shown).
GARP confers regulatory function to human 
antigen-specific Th cells
The above results indicate that GARP is sufficient to cause Treg-
like phenotypic and transcriptional changes in antigen-specific Th
cells. Because the hallmark of Treg cells is their anergic prolifera-
tive response and suppressor function, we stimulated ThGARP
cells to assess their functional properties. Ectopic expression of
GARP in alloantigen-specific Th cells severely reduced their prolif-
erative capacity (Fig. 4A), which could be partially reversed by
exogenous IL-2 (data not shown). Such an anergic proliferative
response was also observed in ThFOXP3 cells but not in ThGFP
control cells (Fig. 4A).
Moreover, ThGARP cells acquired a strong suppressor activity
equivalent to the activity found in Treg cells (Fig. 4B). Suppression
was cell-contact dependent, as it was blocked by a transwell mem-
brane (Fig. 4B). Importantly, both, anergy and suppressor func-
tion, were more pronounced in ThGARP cells compared to
ThFOXP3 cells.
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Fig. 4 Anergy and suppressor function induced
by overexpression of GARP in human alloanti-
gen-specific Th cells. (A) Treg cells and Th cells
as in Figs 1–3 were stimulated for proliferation
using irradiated allogeneic EBV B cells (stim.);
bkg.  background proliferation. Proliferation
was assessed at day 3 by measuring incorpo-
ration of H3-thymidin (cpm). (B) Treg and Th
cells as in (A) were tested for suppressor func-
tion of alloantigen-stimulated ThGFP cells at a
ratio of 1 to 1 either separated by a transwell
membrane (no contact, upper panel) or without
separation (cell contact, middle panel); lower
panel represents induced ThGFP cell prolifera-
tion without the addition of a potential suppres-
sor or control cell population. Proliferation was
assessed at day 3. Similar results were
obtained using antigen-specific Th cells as
responder cells instead of ThGFP cells (Fig. S6B).
(C) Single donor platelets as natural source of
GARP cells was tested for suppressor func-
tion of alloantigen-stimulated Th cells at indi-
cated ratios as in (B); addition of Th and Treg
cells as in (B) at a ratio of 1:1 were included as
negative and positive control of suppressor
function, respectively.
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To investigate a potential direct role of GARP in the suppres-
sion of Th cell proliferation, we used platelets as natural source of
GARP cells [23] in a suppressor assay as in Fig. 4. No suppres-
sion of Th cell proliferation was observed (Fig. 4C). Similar results
were obtained with GARP expressing 293 or Jurkat T cells (data
not shown). Thus, ectopic expression of GARP in antigen-specific
Th cells was sufficient to reprogram TCR signalling to induce
anergy and suppressor functions similar to Treg cells via induction
of Treg-signature of transcriptional control and induction and
maintenance of a regulatory program.
Positive feedback loop between GARP and FOXP3
in human Treg cells
The above results indicate that overexpression of GARP controls
FOXP3 in Th cells. Similarly, overexpression of FOXP3 induces
GARP. This suggests interdependence via a positive feedback loop.
To prove the relevance of this feedback loop we down-regulated
GARP and FOXP3 in the established CD4CD25hi-derived Treg cell
line described above [15] with siRNA using a lentiviral vector sys-
tem. Confirmation of FOXP3 expression, lack of IL-2 induction,
anergy, and suppressor function of this Treg cell line is presented
Fig. S4. Treg cells transduced with specific siRNA for GARP, FOXP3
or an irrelevant control were isolated by cell-sorting for GFP
included as marker in the lentiviral vector.
Quantitative real-time RT-PCR analysis of sorted transductants
revealed that irrelevant siRNA did affect neither FOXP3 and GARP
expression nor impaired regulatory function of Treg cells (data not
shown). In contrast, GARP-specific siRNA mediated down-regulation
of GARP in Treg cells (TregsiGARP) as demonstrated in Fig. 5A.
This down-regulation was associated with concurrent down-regu-
lation of FOXP3 mRNA (Fig. 5A). This down-regulation of GARP
and FOXP3 was associated with some phenotypic changes,
including impaired induction of CD83 and CD27, both known to
regulate FOXP3 [22, 35], suggesting an interrelated network of
FOXP3-regulating systems in Treg cells, and down-regulation of
CD25 (Fig. 5B). More importantly, TregsiGARP and TregsiFOXP3
cells revealed comparable impairments of their suppressor activ-
ity (Fig. 5C) and improvement of proliferative capacity in the pres-
ence of IL-2 (Fig. 5C). Together, these results demonstrate com-
pellingly a positive feedback loop between GARP and FOXP3 in
human Treg cells, which is an essential component of a higher-
order regulation for the maintenance of the regulatory phenotype.
GARP represents a specific marker of activated
CD4CD25hi-derived Treg cells
Natural Treg cells and TGF--induced Treg cells differ in some
aspects [36] although many phenotypic and functional features
are common, including high expression of FOXP3 [37]. We there-
fore ask whether enhanced FOXP3 expression in TGF--induced
Treg cells would lead to an up-regulation of GARP. Sorted
CD4CD25 Th cells were stimulated with anti-CD3/anti-CD28/IL-
2 in the presence of TGF-1. Quantitative real-time RT-PCR analy-
sis revealed that GARP was not up-regulated in such TGF-
1-induced Th cells although FOXP3 was present at high levels 
(Fig. S5A) and the cells displayed suppressor function (Fig. S5B).
Thus, GARP is not required for the function of induced Treg cells
arguing that natural and induced Treg cell might represent alterna-
tive differentiation stages of suppressor cells. Moreover, lack of
GARP induction might also explain the only transient and partial
phenotype of such TGF-1-induced regulatory Th cells [38].
GARP and FOXP3 are co-regulated during thymic
Treg cell development
The positive feedback loop between GARP and FOXP3 in Treg cells
implies that both genes should be co-regulated during thymic Treg
cell development. Therefore, from healthy thymi of seven human
donors, we isolated double-positive (CD4CD8) and single-
positive (CD4CD8) thymocytes and separated them into CD25
and CD25 fractions. Quantitative real-time RT-PCR showed that
expression levels of both GARP and FOXP3 were found at signifi-
cant higher levels in CD25 single- and double-positive thymocytes
compared to their CD25 counterparts (Fig. 5D). Thus, the positive
feedback loop between GARP and FOXP3 might already be active
in developing thymic Treg cells.
Together, these results show that overexpression of GARP
reprograms alloantigen-specific Th cells towards a regulatory phe-
notype via sustained expression of GARP and FOXP3. Unlike retro-
viral overexpression of FOXP3 [15, 39], overexpression of GARP
induces a stable regulatory phenotype in antigen-specific Th cells
that was followed up for more than three months of in vitro anti-
gen-specific stimulation and expansion. The phenotype was not
changed by cryopreservation (Fig. S6). Identical results were
obtained with five independent transductions of alloantigen-
 specific Th cell lines from three individual donors. Hence, GARP
represents a receptor involved higher-order control of sustained
expression of FOXP3 with the potential to convert disease-
 associated antigen-specific effector T towards regulatory T cells.
LGMN and LGALS3 are constituents 
of the GARP-FOXP3 feedback loop
Our previous results showed that LGALS3 and LGMN [15] were up-
regulated in alloantigen-specific Th cells transduced with FOXP3.
Both proteins were also induced by GARP (Fig. 2B, Fig. S2).
Because LGMN and LGALS3 are expressed at sustained levels also
in activated Treg cells similar to GARP and FOXP3, a potential con-
tribution to the GARP-FOXP3 feedback loop could be suggested.
Therefore, we retrovirally transduced LGMN (ThLGMN) and LGALS3
(ThLGALS3) in antigen-specific Th cells as described above.
Flow-cytometry and immunoblot analysis of ThLGMN cells
revealed that LGMN protein expression was comparable between
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ThLGMN, ThGARP and ThFOXP3 cells but less up-regulated in
ThLGALS3 cells (Fig. S2B). LGALS3 protein expression was up-
regulated in ThLGALS3 cells. Interestingly, LGALS3 protein
expression was higher in ThGARP, ThFOXP3 and Treg cells and
even ThLGMN cells compared to ThLGALS3 cells (Fig. 2B). This
suggests that LGALS3 acts down-stream of GARP, FOXP3 and
LGMN. As serine-6 phosphorylation of LGALS3 has been reported
to control its function [40], we tested whether deletion of this
caseine-kinase I site would affect its FOXP3-inducing capacity.
Analyses of FOXP3 expression in activated Th cells transduced
with either wild-type or serine-to-alanine mutant LGALS3 revealed
the importance of serine-6, because the mutant LGALS3 did not
induce FOXP3 (Fig. S7A).
To understand the impact of LGMN and LGALS3 on the regu-
lation of GARP and FOXP3 we analysed our alloantigen-specific Th
cells transduced with LGMN and LGALS3 for expression of GARP
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Fig. 5 Positive feedback loop between
GARP and FOXP3 in human Treg cells. (A)
Real-time RT-PCR analysis of GARP and
FOXP3 expression in human Treg cells,
lentivirally transduced with siRNA con-
structs specific for FOXP3 (TregsiFOXP34),
GARP (TregsiGARP4) or non-specific con-
trol (TregsiGL4). Relative mRNA expression
of Th cells was arbitrarily set as 1. (B) The
same cells as in (A) were analysed for sur-
face expression of CD83, CD27, and CD25
following antigen-specific stimulation with
EBV B cells and IL-2. (C) Impairment of
suppressor function of TregsiFOXP34 and
TregsiGARP1 cells of compared to TregsiGL4
cells was assessed in a suppressor assay at
a cell ratio of 1:1 as described in Fig. 4. (D)
Relative expression of GARP and FOXP3
mRNA in the indicated thymic T-cell sub-
sets of normal donors (open symbols),
assessed by TaqMan assay, normalized to
the expression of -actin, is represented;
black symbols  mean of relative mRNA
expression, rel.  relative, *  P  0.002
by 2-sided Student’s t-test.
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and FOXP3. Analysis under resting conditions revealed that GARP
protein expression was only minimally affected in ThLGMN and
ThLGALS3 cells (Fig. 1D), while FOXP3 protein was obviously
induced but not reaching the levels detected in ThGARP or Treg
cells (Fig. 2A). Levels of CD25, CTLA4 and CD33 in ThLGMN and
ThLGALS3 cells did also not reach that observed in ThGARP and
Treg cells (Fig. 2B), whereas CD27 was obviously induced in
ThLGMN similar to ThFOXP3 cells (Fig. 2B). Similar to ThGARP and
ThFOXP3 cells, LGMN and LGALS3 overexpression did not affect
CD83 or GITR expression (Fig. 2B).
Because activation of Th cells up-regulates expression of
FOXP3, we tested ThLGMN and ThLGALS3 cells for expression of
FOXP3, LGALS3 and GARP after antigen-specific stimulation.
Activation of ThLGMN and ThLGALS3 cells clearly enhanced
FOXP3, LGALS3, but not GARP protein expression (Figs 1E and
2C). Nevertheless, levels of FOXP3 and LGALS3 never reached lev-
els observed in ThGARP and Treg cells. This suggests an involve-
ment of LGMN and LGALS3 in the GARP-FOXP3 feedback loop
mainly following T-cell activation.
LGMN and LGALS3 induce a partial Treg-signature
We extended our analysis to the transcriptional control of genes of
the Treg-signature. Quantitative RT-PCR revealed repression of IL-2
transcription in ThLGMN and ThLGALS3 cells (Fig. 3A). Similarly,
only minimal induction of IL1R2 and UBD mRNA (Fig. S2A) was
observed, indicating partial FOXP3-dependent transcriptional con-
trol. Interestingly, although FOXP3 and GARP mRNA was highly
elevated in ThLGMN and ThLGALS3 cells (Fig. S3B), the presence
of such levels of specific mRNA was not sufficient to induce Treg-
like protein expression (Figs 1D and 2B), suggesting post-tran-
scriptional control of GARP and FOXP3 expression.
In line with the lower levels of FOXP3 and GARP expression,
genes of the extended Treg-signature were not up-regulated in
ThLGMN and ThLGALS3 cells. These included RYR-1, HPGD and
CPE (Fig. S3A). A further difference represented the up-regulation
of IL7R observed only in ThLGMN cells (Fig. S3A). In contrast,
KLF-2 induction was observed only in ThLGALS3 but not ThLGMN
cells (Fig. 3C). Because serine-6 phosphorylation of LGALS3 was
an essential prerequisite to induce FOXP3, we tested the effects of
mutant LGALS3 on the expression of GARP and LGMN. Under
resting and activated conditions, the mutant LGALS3 was unable
to induce GARP and LGMN, corroborating the proposed interrela-
tion of LGALS3 with these genes via FOXP3 (Fig. S7B).
Interestingly, KLF-2 was not affected by the serine-6 mutation of
LGALS3, suggesting that LGALS3 also regulates some gene
expression down-stream of FOXP3 independent of its phosphory-
lation (Fig. S7B).
As expected, the functional changes observed in ThLGMN and
ThLGALS3 cells were only minor (Fig. 4A) and no significant sup-
pressive activity was observed (Fig. 4B). Thus, LGMN and LGALS3
appear to play a minor and redundant role in the GARP-FOXP3
feedback loop. In line with that is the fact that LGMN and LGALS3
knock-out mice do not show obvious Treg cell deficiencies [41, 42].
Discussion
In this study, we demonstrate that GARP represents a key recep-
tor that is specifically induced in human CD4CD25hi regulatory 
T cells upon TCR stimulation. Unlike other Treg markers like FOXP3,
CD25 and CTLA4 that are shared between Treg and activated
CD4CD25 Th cells, GARP is not induced in human naïve
CD4CD25 Th and antigen-specific Th cells following TCR acti-
vation, nor in TGF-1-induced Treg cells. Thus, GARP represents a
specific marker suitable to differentiate natural derived
CD4CD25hi Treg cells from activated effector Th cells and induced
Treg cells. We further demonstrate that GARP dominantly controls
FOXP3 via a positive feedback loop able to stably reprogram anti-
gen-specific Th cells towards Treg cells. Thus, GARP plays a key
role in peripheral and most likely thymic Treg cells, and might
serve as an intrinsic control mechanism that ensures the proper
induction and stabilization of sustained high levels of FOXP3 safe-
guarding the regulatory program.
GARP encodes a receptor of yet unknown specificity. Thus far,
detailed analysis of the spatio-temporal expression in mice 
suggested a potential role of GARP in organogenesis at the 
neuromuscular and dermal-epidermal junctions [43]. In lymphoid
organs of mice, the expression of GARP was restricted to endothe-
lial and megakaryocytic cells [23, 43], suggesting a role in coagu-
lation that has recently been confirmed in a coagulation model in
zebrafish [44]. Because Treg cells represent only a minor population
of human CD4 T cells and GARP protein expression is induced in
Treg cells only following TCR stimulation, detection of GARP
expression in Treg cells might have been missed thus far [23].
GARP-associated signalling pathway and its potential ligand
can only be speculated upon. The C-terminal PDZ motif of GARP
might be involved as a protein–protein interaction module besides
being involved in regulation of GARP protein level and cell surface
expression. Although the short cytoplasmic tail of GARP suggests
the existence of a signalling co-receptor as suggested recently
[23], mutation of the PDZ motif alone is sufficient to impair
FOXP3-independent inhibition of ionomycine-induced NFAT acti-
vation assessed in A5 cells. Inhibition of NFAT by GARP might be
the reason for the previously reported impairment of IL-2 in
human GARP-transduced T cells with concurrent down-regulation
of FOXP3 [45]. These authors showed that transduction of GARP
or GARP without the cytoplasmic tail were equally efficient in par-
tially inducing FOXP3 in human T cells [45]. In contrast, our
results show that GARP itself does not simply represent a sup-
pressor molecule, because platelets that naturally express GARP
do not exerted suppressor activity.
Whatever the mechanisms, with the functional characteriza-
tion of LGMN and LGALS3, we could reveal some insights into
the complex regulatory network controlled by the GARP-FOXP3
feedback loop. Unlike GARP, overexpression of LGMN and
LGALS3 in Th cells did not induce sustained high levels of
FOXP3 and GARP but enhanced FOXP3 and GARP expression
mainly following TCR stimulation. Thus, LGMN and LGALS3
were not able to induce a stable regulatory phenotype and 
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represent minor and redundant constituents of the FOXP3 reg-
ulating system controlled by GARP.
LGMN is made as an inactive pro-enzyme that requires auto-
catalytic sequential cleavage to gain activity, localized in receptor-
recycling compartments of endosomes/lysosomes [46, 47].
Although the mechanism of LGMN-mediated FOXP3 regulation
following TCR stimulation remains speculative, it should differ
from GRAIL, an E3-ubiquitin ligase with a similar localization in
receptor-recycling compartments. GRAIL has been reported to be
sufficient to convert murine T cells to a regulatory phenotype via
induction of TGF- in the absence of FOXP3 [48]. Because anti-
gen-specific stimulation of our differentiated effector Th cells in
the presence of TGF- did not induced up-regulation of FOXP3
(data not shown), a significant impact of TGF- signalling to the
effects of LGMN can be excluded. Nevertheless, LGMN might con-
trol some other important cell-surface associated signalling com-
ponents or their recycling, enhancing the Th cell inherent capacity
to induce FOXP3.
Similarly, the mechanism of LGALS3-mediated GARP and
FOXP3 induction remains to be elucidated. Importantly, mutagen-
esis of LGALS3 at position 6 impaired its FOXP3-inducing func-
tion, establishing the importance of this potential CK1-phosphory-
lation site. The molecular mechanisms of LGALS3 action might
include the modulation of the transcription factors NFAT and AP-1,
reported to be activated by LGALS3 in Jurkat T cells [49], because
both factors are involved in the control of FOXP3 transcription in
human T cells [50]. As expected, the impaired induction of FOXP3
by the mutant LGALS3 was accompanied by the inability to induce
GARP and LGMN. Although serine-6 phosphorylation of LGALS3
has been described as important checkpoint in the control of
LGALS3, some phosphorylation independent unique functions
have also been reported [40]. In line with that, the serine-6 mutant
LGALS3 had nearly the same effect on the expression of KLF-2,
suggesting that KLF-2 might be regulated by FOXP3 via LGALS3
independent on its serine-6 phosphorylation.
In conclusion, we discovered GARP as a key receptor control-
ling FOXP3 in human CD4CD25hi Treg cells following TCR activa-
tion. GARP is sufficient to reprogram human alloantigen-specific
Th cells towards regulatory T cells via induction of sustained high
levels FOXP3, presented as simplified model in Fig. 6.
Furthermore, we established a positive feedback loop between
GARP and FOXP3, reminiscent of positive auto-regulation ensur-
ing formation and maintenance of high concentrations of impor-
tant ‘master regulators’ of cell differentiation [51, 52]. With that
GARP represents an epigenetic stabilizing system that allows the
development of a permanent suppressor cell lineage, as sug-
gested recently [53], and acts as a Treg cell-intrinsic tolerance
mechanism as Treg cells are potentially auto-reactive [54].
Together, our findings provide compelling evidence of a GARP-
FOXP3 positive feedback loop that is interrelated with a regulatory
network including LGALS3, LGMN and other FOXP3-regulating
genes like CD33, CD27 and CD83, providing a conceptual frame-
work for the molecular definition of the regulatory program [14].
This opens up the possibility for generation of antigen-specific
regulatory T cells for clinical applications. It further will provide
the basis to develop new strategies and tools to induce or inhibit
Treg cells in chronic infection, tumour immunotherapy, autoim-
mune diseases and transplantation.
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Fig. S1 Alignment of human GARP with the structure of the
ectodomain of human TLR3. (A) Comparison of the ectodomain of
TLR3 (pdb-id: 2A0Z) and GARP, conserved sequences are indi-
cated by blue boxes, strictly conserved residues are highlighted
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Fig. 6 Simplified model of the reprogramming or ‘transdifferentation’ of
effector towards regulatory T cells via the GARP-FOXP3 positive feed-
back loop. The upper part illustrates the change in the ‘quality’ of TCR
signalling outcome from effector (green) towards regulatory (green) TCR
signalling. Thus, each TCR stimulation enhances the positive feedback
indicated by the size of the feedback loop illustrated in the middle. For
simplicity, other components of the regulatory network described, like
LGALS3, LGMN, CD33, CD27 and CD83 or direct impairment of NFAT by
GARP have been excluded. Identification of further components, fine 
tuning, timed-sequential expression and interconnectivity between the
components of the regulatory network represents a major challenge for
the molecular definition of the regulatory program.
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white-on-red, and similar residues indicated by red characters.
Secondary structure elements of the TLR3 structure are indicated
by arrows ( strand), coils (helices) and TT (turns). (B) Ribbon
diagram of a hypothetical GARP dimmer model, based on the
dimerization proposed for TLR3. The prominent loops at 296–308
and 421–432 of GARP () could have similar functions for dimer-
ization as proposed for TLR3. Putative glycolysation sites are indi-
cated with space-filling representations.
Fig. S2 GARP induced transcriptional control. (A) Analysis of LGMN,
UBD, IL1R2, and GARP mRNA by semi-quantitative RT-PCR in Th
cells transduced with GARP, FOXP3, LGMN, LGALS3, and GFP as
described in Figs 1–4. cDNA was tested in threefold dilutions start-
ing with 1:3 using RPS9 as housekeeping control. (B) Western blot
analysis of LGMN protein expression in the same cells as in (A).
Fig. S3 GARP induces genes of the extended Treg-signature. (A)
Semi-quantitative RT-PCR analysis of IL7R, CPE, RYR-1 and
HPGD in Th cells as in Figs 1–4 under resting conditions (no stim.)
and 3 days after stimulation with anti-CD3 and 100 U/ml IL-2 as
described in Fig. S1. (B) Quantitative real-time RT-PCR analysis of
GARP and FOXP3 in Th cells as in (A) tested under resting condi-
tions and 3 days after stimulation as in (A). Relative mRNA
expression of ThGFP cells was arbitrarily set as 1.
Fig. S4 Characterization of the Treg cell line used in this study and
for siRNA experiments. (A) This alloantigen-reactive Treg cells line
(TregTHU) used, has been established and characterized in detail
recently [15]. These cells constitutively express known Treg-mark-
ers, FOXP3, LGALS3, and CD25 are shown as selected examples.
For comparison T cells derived from sorted CD4CD25 Th cells
were stimulated with the same allogeneic EBV B cells and IL-2 in
the presence of vehicle or 10 ng/ml TGF-1. Analysis was done at
day 7 after stimulation. (B) The same cells as in (A) were stimu-
lated with anti-CD3/-CD28 DynalBeads (Invitrogen) and IL-2 for 
6 hrs in the presence of 10 g/ml brefeldin and tested for intracel-
lular IL-2 and FOXP3 expression. Allo-antigen specific Th cells
served as control. (C) Lentiviral transduction efficacy of the Treg
cells as in (A) is similar as compared to Th cells. (D) The hallmark
feature of Treg cells, anergy and suppressor function, are pre-
served over a period of six months of in vitro expansion of the
same Treg cells as in (A) and Figs 1–5.
Fig. S5 GARP is not up-regulated in TGF-1-induced Treg cells. (A)
Sorted CD4CD25 Th cells were stimulated with anti-CD3/-
CD28/IL-2 without (Th), in the presence of solvent (Thvehicle), and
10 ng/ml human TGF-1 (ThTGF-1) as in Fig. S4. Expression of
GARP and FOXP3 mRNA was assessed at day 6 by real-time RT-
PCR as in Fig. 1. (B) TGF-1-induced Treg cells as in (A) were
tested for proliferation and suppressor function (upper panel) and
proliferation with exogenous IL-2 (lower panel); bkg.  back-
ground proliferation, stim.  T-cell proliferation induced by irradi-
ated allogeneic EBV B cells. Proliferation was assessed at day 3 by
measuring incorporation of H3-thymidin (cpm).
Fig. S6 Anergy and suppressor function in alloantigen-specific Th
cells transduced with GARP following cryopreservation. (A) Treg
cells (Treg cell lines MPO and HG [15]) and Th cells as in Figs 1–4
were stimulated for proliferation using irradiated EBV B cells in the
absence (stim.) or presence of IL-2 (stim.IL-2) 1 week after thaw-
ing cryopreserved cells; bkg.  background proliferation.
Proliferation was assessed at day 3 by measuring incorporation of
H3-thymidin (cpm). Treg and Th cells as in (A) were tested for sup-
pressor function of alloantigen-stimulated parental Th cells at a ratio
of 1:1. Percent inhibition of Th cell proliferation by the addition of
retrovirally engineered Th cells is indicated, setting addition of wilt-
type Th cells (Th/Th) as 100%. Proliferation was assessed at day 3.
Fig. S7 Effects of S6A-mutant LGALS3 on gene expression. (A) Th
cells transduced with either wild-type (ThLGALS3) or mutant
(ThLGALS3S6A) were analysed for FOXP3 and CD25 expression at
day 3 following stimulation with anti-CD3 and 100 U/ml IL-2 com-
pared to ThGFP cells. (B) Quantitative real-time RT-PCR analysis of
GARP, LGALS3, LGMN and KLF-2 expression of the same cells as
in (A). Th cells were tested under resting conditions and 3 days
after stimulation with anti-CD3 and 100 U/ml IL-2. Relative mRNA
expression of ThGFP cells was arbitrarily set as 1.
Table S1 Differential gene expression of resting and activated
CD4CD25hi Treg versus CD4CD25 Th cells analysed ex vivo as
detected by array analysis
Table S2 Differential gene expression Treg cells, ThGARP and
ThFOXP3 compared to ThGFP cells
This material is available as part of the online article from:
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1582-
4934.2009.00782.x
(This link will take you to the article abstract).
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors.
Any queries (other than missing material) should be directed to
the corresponding author for the article.
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